Skip to content
Linkedin Twitter Instagram Vimeo Youtube
  • Science
  • Clinical Trials
    • ALZHEIMER’S DISEASE
    • AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    • FRAGILE X SYNDROME (FXS)
    • SCHIZOPHRENIA
  • Media
    • PRESS RELEASES
    • IN THE NEWS
  • Blog
  • Team
  • Contact Us
  • Science
  • Clinical Trials
    • ALZHEIMER’S DISEASE
    • AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    • FRAGILE X SYNDROME (FXS)
    • SCHIZOPHRENIA
  • Media
    • PRESS RELEASES
    • IN THE NEWS
  • Blog
  • Team
  • Contact Us

Phase 2 Trial Open Enrollment for SPG302, First Synaptic Regenerative Approach to Treat Schizophrenia

Tagged Schizophrenia

Info@spinogenix.com

Linkedin Twitter Instagram
  • Science
  • Clinical Trials
  • Media
  • Blog
  • Team
  • Contact Us
  • Privacy Notice
  • Disclaimer
  • Science
  • Clinical Trials
  • Media
  • Blog
  • Team
  • Contact Us
  • Privacy Notice
  • Disclaimer